Short Interest in Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Grows By 97.5%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 1,177 shares, an increase of 97.5% from the May 14th total of 596 shares. Based on an average trading volume of 10,593 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.

Ascentage Pharma Group International Trading Up 2.9%

Shares of AAPG stock traded up $0.49 during trading hours on Friday, reaching $17.60. The company’s stock had a trading volume of 11,877 shares, compared to its average volume of 9,674. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. Ascentage Pharma Group International has a fifty-two week low of $16.92 and a fifty-two week high of $48.45. The firm’s 50 day simple moving average is $22.10 and its 200-day simple moving average is $24.75.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.52) earnings per share for the quarter. The company had revenue of $24.72 million during the quarter. As a group, research analysts predict that Ascentage Pharma Group International will post -0.96 EPS for the current year.

Analysts Set New Price Targets

AAPG has been the topic of a number of recent research reports. BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Monday, April 13th. China Intl Cap upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, April 6th. B. Riley Financial started coverage on Ascentage Pharma Group International in a report on Wednesday. They issued a “buy” rating and a $45.00 target price on the stock. Deutsche Bank Aktiengesellschaft started coverage on Ascentage Pharma Group International in a report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $46.43.

Institutional Investors Weigh In On Ascentage Pharma Group International

Hedge funds have recently modified their holdings of the company. UBS Group AG boosted its holdings in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $391,000. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at $383,000. Finally, XY Capital Ltd boosted its holdings in shares of Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares in the last quarter.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical?stage biopharmaceutical company focused on developing small?molecule therapeutics that modulate programmed cell death pathways, including the Bcl?2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.